Prostate Management Diagnostics Raises $1.06M in Series A Financing

PMDI_logoProstate Management Diagnostics, Inc.,  closed a $1.06m first tranche of a Series A financing.

The funds will initially be used to develop a test to differentiate between indolent and aggressive disease in patients newly diagnosed with early stage disease.

Founded by the non-profit Peter Michael Foundation to commercialize discovery research being conducted by The Genome Institute at Washington University School of Medicine in St. Louis and led by Dr. Elaine Mardis, the Robert E. and Louise F. Dunn Distinguished Professor of Medicine and Co-Director of The Genome Institute, and Dr. Christopher Maher, Assistant Professor of Medicine and Assistant Director at The Genome Institute, PMDI aims to create new tests to identify and stratify patients at risk for and diagnosed with prostate cancer.



Join the discussion